A Phase II Safety and Tolerability Study of TCB008 in Patients With COVID-19

Summary

A Phase II safety and tolerability study of expanded gamma delta T cell lymphocytes (TCB008) in patients diagnosed with COVID-19.

Timeline

Start

2021-12-13

Primary completion

2022-04-13

Completion

2022-04-13

Outcome

Outcome not reported

Stopped: “The study was stopped because of the current status of the COVID-19 epidemic in the United Kingdom, and also because the trial involved parenterally administered IMP and a period of inpatient care and extensive outpatient visits and investigations.”

Drugs

Indications